An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)

Ash Bullement,1 Emma S Knowles,1 Merel Langenfeld,2 Gil Reynolds Diogo,3 Jameel Nazir,4 Daniel Eriksson4 1Delta Hat, Nottingham, UK; 2Sobi, Woluwe-Saint-Lambert, Belgium; 3Sobi, Cambridge, UK; 4Sobi, Stockholm, SwedenCorrespondence: Daniel Eriksson Email daniel.eriksson@sobi.comIntroduction: Systemi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bullement A, Knowles ES, Langenfeld M, Diogo GR, Nazir J, Eriksson D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	still’s disease systemic juvenile idiopathic arthritis anakinra economic comparison treatment strategies first line. Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/96036ef89d5948868de31096e9d56e17
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:96036ef89d5948868de31096e9d56e17
record_format	dspace
spelling	oai:doaj.org-article:96036ef89d5948868de31096e9d56e172021-12-02T17:16:23ZAn Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)1179-156Xhttps://doaj.org/article/96036ef89d5948868de31096e9d56e172021-09-01T00:00:00Zhttps://www.dovepress.com/an-economic-comparison-of-treatment-strategies-with-anakinra-in-system-peer-reviewed-fulltext-article-OARRRhttps://doaj.org/toc/1179-156XAsh Bullement,1 Emma S Knowles,1 Merel Langenfeld,2 Gil Reynolds Diogo,3 Jameel Nazir,4 Daniel Eriksson4 1Delta Hat, Nottingham, UK; 2Sobi, Woluwe-Saint-Lambert, Belgium; 3Sobi, Cambridge, UK; 4Sobi, Stockholm, SwedenCorrespondence: Daniel Eriksson Email daniel.eriksson@sobi.comIntroduction: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex autoinflammatory disease with substantial morbidity, often characterized by fever, rash, and muscle pain, amongst other symptoms. Biologic agents, such as anakinra, have been successfully used to treat patients internationally, but their usage in some regions is limited to patients that have failed to achieve clinically inactive disease with corticosteroids and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Use of anakinra early in the disease course leads to better clinical outcomes; however, longer-term costs for this treatment strategy have not been established. This study compares the economic implications of first-line versus later-line availability of anakinra for patients with sJIA.Methods: Data for patients treated with first-line anakinra were identified from a single-center, prospective study and compared to a combination of published trial and economic evaluation information to facilitate a comparison to later-line anakinra (ie, following corticosteroids + csDMARDs). Costs were estimated for product acquisition and medical resource utilization (MRU), including planned outpatient visits and unplanned hospital admissions. Total costs over a 5-year horizon were compared.Results: Total 5-year product acquisition cost for the first-line anakinra strategy was € 24,021, and for later-line anakinra was € 20,471. The corresponding MRU costs were € 19,197 (first-line) versus € 25,425 (later-line). Overall 5-year costs (product acquisition and MRU) were lower for the first-line strategy (€ 43,218 versus € 45,896).Conclusion: The use of anakinra for patients with sJIA in the first-line setting is efficacious to induce and sustain inactive disease, and the findings of this study show that this treatment strategy leads to cost savings through reduced medical expenditure.Keywords: Still’s disease, systemic juvenile idiopathic arthritis, anakinra, economic comparison, treatment strategies, first lineBullement AKnowles ESLangenfeld MDiogo GRNazir JEriksson DDove Medical Pressarticlestill’s diseasesystemic juvenile idiopathic arthritisanakinraeconomic comparisontreatment strategiesfirst line.Diseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 13, Pp 257-266 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	still’s disease systemic juvenile idiopathic arthritis anakinra economic comparison treatment strategies first line. Diseases of the musculoskeletal system RC925-935
spellingShingle	still’s disease systemic juvenile idiopathic arthritis anakinra economic comparison treatment strategies first line. Diseases of the musculoskeletal system RC925-935 Bullement A Knowles ES Langenfeld M Diogo GR Nazir J Eriksson D An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
description	Ash Bullement,1 Emma S Knowles,1 Merel Langenfeld,2 Gil Reynolds Diogo,3 Jameel Nazir,4 Daniel Eriksson4 1Delta Hat, Nottingham, UK; 2Sobi, Woluwe-Saint-Lambert, Belgium; 3Sobi, Cambridge, UK; 4Sobi, Stockholm, SwedenCorrespondence: Daniel Eriksson Email daniel.eriksson@sobi.comIntroduction: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex autoinflammatory disease with substantial morbidity, often characterized by fever, rash, and muscle pain, amongst other symptoms. Biologic agents, such as anakinra, have been successfully used to treat patients internationally, but their usage in some regions is limited to patients that have failed to achieve clinically inactive disease with corticosteroids and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Use of anakinra early in the disease course leads to better clinical outcomes; however, longer-term costs for this treatment strategy have not been established. This study compares the economic implications of first-line versus later-line availability of anakinra for patients with sJIA.Methods: Data for patients treated with first-line anakinra were identified from a single-center, prospective study and compared to a combination of published trial and economic evaluation information to facilitate a comparison to later-line anakinra (ie, following corticosteroids + csDMARDs). Costs were estimated for product acquisition and medical resource utilization (MRU), including planned outpatient visits and unplanned hospital admissions. Total costs over a 5-year horizon were compared.Results: Total 5-year product acquisition cost for the first-line anakinra strategy was € 24,021, and for later-line anakinra was € 20,471. The corresponding MRU costs were € 19,197 (first-line) versus € 25,425 (later-line). Overall 5-year costs (product acquisition and MRU) were lower for the first-line strategy (€ 43,218 versus € 45,896).Conclusion: The use of anakinra for patients with sJIA in the first-line setting is efficacious to induce and sustain inactive disease, and the findings of this study show that this treatment strategy leads to cost savings through reduced medical expenditure.Keywords: Still’s disease, systemic juvenile idiopathic arthritis, anakinra, economic comparison, treatment strategies, first line
format	article
author	Bullement A Knowles ES Langenfeld M Diogo GR Nazir J Eriksson D
author_facet	Bullement A Knowles ES Langenfeld M Diogo GR Nazir J Eriksson D
author_sort	Bullement A
title	An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
title_short	An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
title_full	An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
title_fullStr	An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
title_full_unstemmed	An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
title_sort	economic comparison of treatment strategies with anakinra in systemic juvenile idiopathic arthritis (sjia)
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/96036ef89d5948868de31096e9d56e17
work_keys_str_mv	AT bullementa aneconomiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT knowleses aneconomiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT langenfeldm aneconomiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT diogogr aneconomiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT nazirj aneconomiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT erikssond aneconomiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT bullementa economiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT knowleses economiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT langenfeldm economiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT diogogr economiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT nazirj economiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia AT erikssond economiccomparisonoftreatmentstrategieswithanakinrainsystemicjuvenileidiopathicarthritissjia
_version_	1718381158705659904

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)

Ejemplares similares